Investment
Features
FeesSafety
Academy
More
Pluang+

Phase 2 trial shows Travelan cuts travelers' diarrhea severity by up to 50%, published in Nature Journal.

Market News
13 Oct 2026
GlobeNewsWire
View Source
Bullish
Phase 2 trial shows Travelan cuts travelers' diarrhea severity by up to 50%, published in Nature Journal.

Immuron Limited published Phase 2 trial results for Travelan, an oral immunotherapy for travelers' diarrhea, in the Nature Journal. The study showed Travelan significantly reduced diarrhea severity and early antibiotic use by up to 71%, despite not meeting primary efficacy endpoints due to a lower placebo attack rate. Travelan also improved gut microbiome health and was safe and well tolerated. Immuron plans further trials with a next-gen formulation to confirm broader protection against bacterial gastrointestinal infections.

The Travelan® Phase 2 study results provide context for health innovation developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 13, 2026 16:11 WIB: Of 128 priced US health-sector stocks tradable on Pluang, 76 rose and 45 fell today. Notable movers include Cytokinetics Inc (CYTK) at USD 61.86 with a 1-day change of -1.48% and a typical hold time of 19 days, Alcon AG (ALC) at USD 65.29 with a 1-day change of +1.46% and Pluang order activity showing 0% Sell / 100% Buy with a typical hold time of 70 days, and Ginkgo Bioworks Holdings Inc (DNA) at USD 11.62 with a 1-day change of -1.44% and Pluang order activity of 35% Sell / 65% Buy with a typical hold time of 7 days.

More News

Holafly launches Ultra Plan combining unlimited data with health and travel support for global travelers

Holafly launches Ultra Plan combining unlimited data with health and travel support for global travelers

Holafly has introduced the Ultra Plan, a new global eSIM subscription that offers unlimited mobile data alongside health and wellness services, including 24/7 medical messaging, mental health sessions, nutrition and fitness coaching, and veterinary a...

Others
Bullish
1 hour ago
Investec Bank sells 2,013 shares of Gooch & Housego on Oct 12, 2026, acting as broker.

Investec Bank sells 2,013 shares of Gooch & Housego on Oct 12, 2026, acting as broker.

Investec Bank plc, acting as advisor and broker for Gooch & Housego plc, sold 2,013 ordinary shares at a price of 1,230 per share on October 12, 2026. This transaction was disclosed under the Takeover Code, indicating a client-serving capacity trade ...

Market News
Neutral
2 hours ago
Sveriges Riksbank auctions 470 billion SEK certificates at 1.75% interest maturing Oct 21, 2026

Sveriges Riksbank auctions 470 billion SEK certificates at 1.75% interest maturing Oct 21, 2026

Sveriges Riksbank announced an auction for certificates totaling 470 billion SEK with an interest rate of 1.75%, maturing on October 21, 2026. The bid and auction dates were October 13, 2026, with settlement on October 14. This auction is part of the...

Market News
Neutral
2 hours ago
New guide launched to help navigate networking events around Jefferies Global Healthcare Conference in London

New guide launched to help navigate networking events around Jefferies Global Healthcare Conference in London

Optimum Strategic Communications and Catalyst Advisors have launched an official Networking Event Guide for the Jefferies Global Healthcare Conference and London Life Sciences Week, held from November 15-20, 2026. The guide consolidates various recep...

Others
Neutral
2 hours ago
Investec Bank discloses share dealings in Gamma Communications on October 12, 2026.

Investec Bank discloses share dealings in Gamma Communications on October 12, 2026.

Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed its trading activities on October 12, 2026. The bank purchased 153,297 ordinary shares at prices between 1094 and 1094.5, and sold 65,648 shares at prices between 1094 ...

Market News
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App